Date: 2012-04-11
Type of information:
phase: 1b-2
Announcement: initiation of the study
Company: Wilex (Germany)
Product: WX-554
Action mechanism: WX-554 is a small-molecule MEK inhibitor. The product is one of five oncology preclinical programmes obtained under the strategic alliance agreed with UCB in January 2009 and is being clinically developed by Wilex. Mitogen activated protein kinase (MEK) has been shown to play a central role in signal transduction. The MEK signalling pathway is over expressed in more than 30% of cancers, resulting in uncontrolled cell growth and proliferation.
Disease: solid tumours
Therapeutic area: Cancer - Oncology
Country: UK
Trial details:
Latest
news: * On April 11, 2012, Wilex has announced the start of a Phase Ib/II trial with the small-molecule MEK inhibitor WX-554. The open-label, dose-escalation study will investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of WX-554 in patients with solid tumours.After a dose escalation part to confirm the biologically effective dose, a dose expansion part will follow, enriched for patients with MEK pathway relevant mutations, to investigate initial clinical activity. The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved this Phase Ib/II trial with WX-554 in January 2012. The study is being conducted within the Experimental Cancer Medicine Centre (ECMC) network in the UK which is jointly supported by Cancer Research UK and the Departments of Health for England, Scotland, Wales and Northern Ireland.
